{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:39:19Z","timestamp":1775180359124,"version":"3.50.1"},"reference-count":43,"publisher":"Informa UK Limited","issue":"14","funder":[{"name":"Emory University SPARK"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Substance Use & Misuse"],"published-print":{"date-parts":[[2024,12,5]]},"DOI":"10.1080\/10826084.2024.2392545","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T05:13:03Z","timestamp":1724044383000},"page":"2055-2063","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Qualitative Assessment of Barriers to Buprenorphine Access: The Role of Pharmacies"],"prefix":"10.1080","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1462-9411","authenticated-orcid":false,"given":"Siara I.","family":"Sitar","sequence":"first","affiliation":[{"name":"Emory Addiction Center, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4216-931X","authenticated-orcid":false,"given":"Courtney R.","family":"Yarbrough","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie J.","family":"Mataczynski","sequence":"additional","affiliation":[{"name":"Emory Addiction Center, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea M.","family":"Peralta","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Kan","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie D.","family":"Crawford","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Kee","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry N.","family":"Young","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Georgia, Athens, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6418-744X","authenticated-orcid":false,"given":"Justine W.","family":"Welsh","sequence":"additional","affiliation":[{"name":"Emory Addiction Center, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,8,18]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.2098"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12307"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxy089"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1787300"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2017.12.009"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102701"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2022.100154"},{"key":"e_1_3_5_10_1","unstructured":"Drug Enforcement Administration Diversion Control Division. (2018). Use of telemedicine while providing medication assisted treatment (MAT). Retrieved June 13 2023 from https:\/\/www.samhsa.gov\/sites\/default\/files\/programs_campaigns\/medication_assisted\/telemedicine-dea-guidance.pdf"},{"key":"e_1_3_5_11_1","unstructured":"Drug Enforcement Administration. (2019). DEA announces enhanced tool for registered drug manufacturers and distributors to combat opioid crisis. https:\/\/www.dea.gov\/press-releases\/2019\/02\/26\/dea-announces-enhanced-tool-registered-drug-manufacturers-and"},{"key":"e_1_3_5_12_1","unstructured":"Drug Enforcement Administration. (2021). DEA qualifying practitioners and DEA qualifying other practitioners announcement. Retrieved December 20 2022 from https:\/\/www.deadiversion.usdoj.gov\/GDP\/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf?mc_cid=8dffbfc637%26mc_eid%3Dd4494a732e"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3711"},{"key":"e_1_3_5_14_1","unstructured":"H.R.6 - 115th Congress. (2017\u20132018). SUPPORT for patients and communities act | Congress.gov | Library of Congress. Retrieved December 2 2019 from https:\/\/www.congress.gov\/bill\/115th-congress\/house-bill\/6"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15314"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2012.01.001"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108729"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0094-5"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06257-4"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ssmqr.2022.100161"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2021.1975749"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.31478\/202004b"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2022.100204"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103321"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2012.031"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/17445647.2023.2270632"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2022.114992"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2019.1616349"},{"key":"e_1_3_5_30_1","unstructured":"National Institute on Drug Abuse. (2023). Drug overdose death rates. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates#:\u223c:text=More%20than%20106%2C000%20persons%20in drugs%20from%201999%20to%202021"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000762"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2021.10.002"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108710"},{"key":"e_1_3_5_34_1","unstructured":"Substance Abuse and Mental Health Services. (2023). Removal of DATA waiver (x-waiver) requirement. Retrieved from April 4 2023 from https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/removal-data-waiver-requirement"},{"key":"e_1_3_5_35_1","first-page":"1","volume-title":"Key substance use and mental health indicators in the United States: Results from the 2021 national survey on drug use and health","author":"Substance Abuse and Mental Health Services Administration","year":"2022","unstructured":"Substance Abuse and Mental Health Services Administration. (2022). Key substance use and mental health indicators in the United States: Results from the 2021 national survey on drug use and health (pp. 1\u2013162). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration."},{"key":"e_1_3_5_36_1","unstructured":"Substance Abuse and Mental Health Services Administration. (2023). DEA SAMHSA extend COVID-19 telemedicine flexibilities for prescribing controlled medications for six months while considering comments from the public. Retrieved June 13 2023 from https:\/\/www.samhsa.gov\/newsroom\/press-announcements\/20230509\/dea-extend-covid19-telemedicine-flexibilities-prescribing-controlled-medications"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103703"},{"key":"e_1_3_5_38_1","unstructured":"The Center for Clinical Management Research CFIR Research Team. (2022). The consolidation framework for implementation research. Retrieved August 11 2020 from https:\/\/cfirguide.org\/"},{"key":"e_1_3_5_39_1","unstructured":"Thielemans M. (2023). Workforce study results also indicate that more women are rising to management positions. Retrieved May 19 2023 from https:\/\/www.aacp.org\/article\/pharmacy-profession-becoming-increasingly-diverse-and-trending-younger-survey-shows"},{"key":"e_1_3_5_40_1","unstructured":"Trahan L. (2021). H.R.2067 - MATE Act of 2021. Retrieved June 13 2023 from https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/2067?q=%7B%22search%22%3A%5B%22MATE+Act+2021%22%2C%22MATE%22%2C%22Act%22%2C%222021%22%5D%7D&s=1&r=1"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2019.1670210"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.121"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.12.015"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201900150"}],"container-title":["Substance Use & Misuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10826084.2024.2392545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T12:58:45Z","timestamp":1730206725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10826084.2024.2392545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,18]]},"references-count":43,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,12,5]]}},"alternative-id":["10.1080\/10826084.2024.2392545"],"URL":"https:\/\/doi.org\/10.1080\/10826084.2024.2392545","relation":{},"ISSN":["1082-6084","1532-2491"],"issn-type":[{"value":"1082-6084","type":"print"},{"value":"1532-2491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isum20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isum20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}